Genome engineering in ophthalmology: Application of CRISPR/Cas to the treatment of eye disease

Progress in Retinal and Eye Research

Volumn 53, Issue , 2016, Pages 1-20

  Hung, Sandy S C ^a   McCaughey, Tristan ^a,b   Swann, Olivia ^c   Pébay, Alice ^a   Hewitt, Alex W ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Cas9; Cpf1; Ethics; Gene editing; Genetic ophthalmology; Inherited retinal disease

Indexed keywords

GUIDE RNA; NUCLEASE; NUCLEOTIDE; RNA; CRISPR ASSOCIATED PROTEIN;

AWARENESS; CELL THERAPY; CRISPR CAS SYSTEM; EYE DISEASE; GENE EDITING; GENE MUTATION; GENETIC ENGINEERING; GENETIC PROCEDURES; HUMAN; HUMAN EMBRYO; HUMAN GENOME; IN VIVO STUDY; MEDICAL ETHICS; NONHUMAN; OPHTHALMOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMISTRY; EYE DISEASES; GENE THERAPY; GENETICS; PROCEDURES;

ANIMALS; CRISPR-ASSOCIATED PROTEINS; CRISPR-CAS SYSTEMS; EYE DISEASES; GENETIC ENGINEERING; GENETIC THERAPY; GENOME, HUMAN; HUMANS;

EID: 84969945265     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2016.05.001     Document Type: Review

References (200)

1. Acland G.M., Aguirre G.D., Ray J., Zhang Q., Aleman T.S., Cideciyan A.V., Pearce-Kelling S.E., Anand V., Zeng Y., Maguire A.M., Jacobson S.G., Hauswirth W.W., Bennett J. Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 2001, 28:92-95.
2. Attarwala H. TGN1412: from discovery to disaster. J. Young Pharm. 2010, 2:332-336.
3. Bae S., Park J., Kim J.S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 2014, 30:1473-1475.
4. Bakondi B., Lv W., Lu B., Jones M.K., Tsai Y., Kim K.J., Levy R., Akhtar A.A., Breunig J.J., Svendsen C.N., Wang S. Vivo CRISPR/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 Rat model of autosomal dominant retinitis pigmentosa. Mol. Ther. 2015, 24:556-563.
5. Baltimore D., Berg P., Botchan M., Carroll D., Charo R.A., Church G., Corn J.E., Daley G.Q., Doudna J.A., Fenner M., Greely H.T., Jinek M., Martin G.S., Penhoet E., Puck J., Sternberg S.H., Weissman J.S., Yamamoto K.R. Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science 2015, 348:36-38.
6. Barrangou R., Fremaux C., Deveau H., Richards M., Boyaval P., Moineau S., Romero D.A., Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007, 315:1709-1712.
7. Bayer R., Spitzer R.L. Edited correspondence on the status of homosexuality in DSM-III. J. Hist. Behav. Sci. 1982, 18:32-52.
8. Beck D. Between relativism and imperialism: navigating moral diversity in cross-cultural bioethics. Dev. World Bioeth. 2014, 15:162-171.
9. Beerli R.R., Barbas C.F. Engineering polydactyl zinc-finger transcription factors. Nat. Biotechnol. 2002, 20:135-141.
10. Berger W., Kloeckener-Gruissem B., Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. Prog. Retin Eye Res. 2010, 29:335-375.
11. Bhaya D., Davison M., Barrangou R. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu. Rev. Genet. 2011, 45:273-297.
12. Bibikova M., Carroll D., Segal D.J., Trautman J.K., Smith J., Kim Y.G., Chandrasegaran S. Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol. Cell Biol. 2001, 21:289-297.
13. Bikard D., Marraffini L.A. Control of gene expression by CRISPR-Cas systems. F1000Prime Rep. 2013, 5:47.
14. Bitinaite J., Wah D.A., Aggarwal A.K., Schildkraut I. FokI dimerization is required for DNA cleavage. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:10570-10575.
15. Boch J., Scholze H., Schornack S., Landgraf A., Hahn S., Kay S., Lahaye T., Nickstadt A., Bonas U. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009, 326:1509-1512.
16. Borry P., Schotsmans P., Dierickx K. What is the role of empirical research in bioethical reflection and decision-making? an ethical analysis. Med. Health Care Philos. 2004, 7:41-53.
17. Bosley K.S., Botchan M., Bredenoord A.L., Carroll D., Charo R.A., Charpentier E., Cohen R., Corn J., Doudna J., Feng G., Greely H.T., Isasi R., Ji W., Kim J.S., Knoppers B., Lanphier E., Li J., Lovell-Badge R., Martin G.S., Moreno J., Naldini L., Pera M., Perry A.C., Venter J.C., Zhang F., Zhou Q. CRISPR germline engineering-the community speaks. Nat. Biotechnol. 2015, 33:478-486.
18. Boye S.E., Boye S.L., Lewin A.S., Hauswirth W.W. A comprehensive review of retinal gene therapy. Mol. Ther. 2013, 21:509-519.
19. Brouns S.J., Jore M.M., Lundgren M., Westra E.R., Slijkhuis R.J., Snijders A.P., Dickman M.J., Makarova K.S., Koonin E.V., van der Oost J. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 2008, 321:960-964.
20. Bult C.J., White O., Olsen G.J., Zhou L., Fleischmann R.D., Sutton G.G., Blake J.A., FitzGerald L.M., Clayton R.A., Gocayne J.D., Kerlavage A.R., Dougherty B.A., Tomb J.F., Adams M.D., Reich C.I., Overbeek R., Kirkness E.F., Weinstock K.G., Merrick J.M., Glodek A., Scott J.L., Geoghagen N.S., Venter J.C. Complete genome sequence of the methanogenic archaeon, Methanococcus jannaschii. Science 1996, 273:1058-1073.
21. Carroll D. Genome engineering with zinc-finger nucleases. Genetics 2011, 188:773-782.
22. Carte J., Wang R., Li H., Terns R.M., Terns M.P. Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes. Genes Dev. 2008, 22:3489-3496.
23. Chen B., Gilbert L.A., Cimini B.A., Schnitzbauer J., Zhang W., Li G.W., Park J., Blackburn E.H., Weissman J.S., Qi L.S., Huang B. Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 2013, 155:1479-1491.
24. Chen S., Sanjana N.E., Zheng K., Shalem O., Lee K., Shi X., Scott D.A., Song J., Pan J.Q., Weissleder R., Lee H., Zhang F., Sharp P.A. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 2015, 160:1246-1260.
25. Cheng A.W., Wang H., Yang H., Shi L., Katz Y., Theunissen T.W., Rangarajan S., Shivalila C.S., Dadon D.B., Jaenisch R. Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res. 2013, 23:1163-1171.
26. Cho S.W., Kim S., Kim Y., Kweon J., Kim H.S., Bae S., Kim J.S. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 2014, 24:132-141.
27. Cho S.W., Lee J., Carroll D., Kim J.S., Lee J. Heritable gene knockout in Caenorhabditis elegans by direct injection of Cas9-sgRNA ribonucleoproteins. Genetics 2013, 195:1177-1180.
28. Christian M., Cermak T., Doyle E.L., Schmidt C., Zhang F., Hummel A., Bogdanove A.J., Voytas D.F. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 2010, 186:757-761.
29. Chu V.T., Weber T., Wefers B., Wurst W., Sander S., Rajewsky K., Kuhn R. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat. Biotechnol. 2015, 33:543-548.
30. Ciavatta V.T., Padove S.A., Boatright J.H., Nickerson J.M. Mouse retina has oligonucleotide-induced gene repair activity. Invest. Ophthalmol. Vis. Sci. 2005, 26:2291-2299.
31. Cideciyan A.V., Hauswirth W.W., Aleman T.S., Kaushal S., Schwartz S.B., Boye S.L., Windsor E.A., Conlon T.J., Sumaroka A., Pang J.J., Roman A.J., Byrne B.J., Jacobson S.G. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum. Gene Ther. 2009, 20:999-1004.
32. Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339:819-823.
33. Courtney D.G., Moore J.E., Atkinson S.D., Maurizi E., Allen E.H., Pedrioli D.M., McLean W.H., Nesbit M.A., Moore C.B. CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting. Gene Ther. 2015, 23:108-112.
34. Craven L., Tuppen H.A., Greggains G.D., Harbottle S.J., Murphy J.L., Cree L.M., Murdoch A.P., Chinnery P.F., Taylor R.W., Lightowlers R.N., Herbert M., Turnbull D.M. Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. Nature 2010, 465:82-85.
35. Crosetto N., Mitra A., Silva M.J., Bienko M., Dojer N., Wang Q., Karaca E., Chiarle R., Skrzypczak M., Ginalski K., Pasero P., Rowicka M., Dikic I. Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nat. Methods 2013, 10:361-365.
36. Cyranoski D. Next-generation stem cells cleared for human trial. Nat. News 2014, 10.1038/nature.2014.15897.
37. Dahlman J.E., Abudayyeh O.O., Joung J., Gootenberg J.S., Zhang F., Konermann S. Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease. Nat. Biotechnol. 2015, 33:1159-1161.
38. Dang Y., Jia G., Choi J., Ma H., Anaya E., Ye C., Shankar P., Wu H. Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency. Genome Biol. 2015, 16:280.
39. Davis B.M., Normando E.M., Guo L., Turner L.A., Nizari S., O'Shea P., Moss S.E., Somavarapu S., Cordeiro M.F. Topical delivery of Avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes. Small 2014, 10:1575-1584.
40. Davis K.M., Pattanayak V., Thompson D.B., Zuris J.A., Liu D.R. Small molecule-triggered Cas9 protein with improved genome-editing specificity. Nat. Chem. Biol. 2015, 11:316-318.
41. Day T.P., Byrne L.C., Schaffer D.V., Flannery J.G. Advances in AAV vector development for gene therapy in the retina. Adv. Exp. Med. Biol. 2014, 801:687-693.
42. Deltcheva E., Chylinski K., Sharma C.M., Gonzales K., Chao Y., Pirzada Z.A., Eckert M.R., Vogel J., Charpentier E. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 2011, 471:602-607.
43. Deveau H., Barrangou R., Garneau J.E., Labonte J., Fremaux C., Boyaval P., Romero D.A., Horvath P., Moineau S. Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J. Bacteriol. 2008, 190:1390-1400.
44. Ding Q., Regan S.N., Xia Y., Oostrom L.A., Cowan C.A., Musunuru K. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 2013, 12:393-394.
45. Ding Q., Strong A., Patel K.M., Ng S.L., Gosis B.S., Regan S.N., Cowan C.A., Rader D.J., Musunuru K. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ. Res. 2014, 115:488-492.
46. Dow L.E., Fisher J., O'Rourke K.P., Muley A., Kastenhuber E.R., Livshits G., Tschaharganeh D.F., Socci N.D., Lowe S.W. Inducible in vivo genome editing with CRISPR-Cas9. Nat. Biotechnol. 2015, 33:390-394.
47. Elguero E., Delicat-Loembet L.M., Rougeron V., Arnathau C., Roche B., Becquart P., Gonzalez J.P., Nkoghe D., Sica L., Leroy E.M., Durand P., Ayala F.J., Ollomo B., Renaud F., Prugnolle F. Malaria continues to select for sickle cell trait in Central Africa. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:7051-7054.
48. Esvelt K.M., Mali P., Braff J.L., Moosburner M., Yaung S.J., Church G.M. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat. Methods 2013, 10:1116-1121.
49. Esvelt K.M., Wang H.H. Genome-scale engineering for systems and synthetic biology. Mol. Syst. Biol. 2013, 9:641.
50. Fonfara I., Le Rhun A., Chylinski K., Makarova K.S., Lecrivain A.L., Bzdrenga J., Koonin E.V., Charpentier E. Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. Nucleic Acids Res. 2014, 42:2577-2590.
51. Fu Y., Foden J.A., Khayter C., Maeder M.L., Reyon D., Joung J.K., Sander J.D. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 2013, 31:822-826.
52. Fu Y., Reyon D., Joung J.K. Targeted genome editing in human cells using CRISPR/Cas nucleases and truncated guide RNAs. Methods Enzymol. 2014, 546:21-45.
53. Fu Y., Sander J.D., Reyon D., Cascio V.M., Joung J.K. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat. Biotechnol. 2014, 32:279-284.
54. Gabriel R., Lombardo A., Arens A., Miller J.C., Genovese P., Kaeppel C., Nowrouzi A., Bartholomae C.C., Wang J., Friedman G., Holmes M.C., Gregory P.D., Glimm H., Schmidt M., Naldini L., von Kalle C. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat. Biotechnol. 2011, 29:816-823.
55. Gaj T., Gersbach C.A., Barbas C.F. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013, 31:397-405.
56. Gasiunas G., Barrangou R., Horvath P., Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E2579-E2586.
57. Gaspar H.B., Cooray S., Gilmour K.C., Parsley K.L., Adams S., Howe S.J., Al Ghonaium A., Bayford J., Brown L., Davies E.G., Kinnon C., Thrasher A.J. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci. Transl. Med. 2011, 3:97ra79.
58. Godde J.S., Bickerton A. The repetitive DNA elements called CRISPRs and their associated genes: evidence of horizontal transfer among prokaryotes. J. Mol. Evol. 2006, 62:718-729.
59. Grant C.A., Ponnazhagan S., Wang X.S., Srivastava A., Li T. Evaluation of recombinant adeno-associated virus as a gene transfer vector for the retina. Curr. Eye Res. 1997, 16:949-956.
60. Guilinger J.P., Thompson D.B., Liu D.R. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat. Biotechnol. 2014, 32:577-582.
61. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., Nadler J., Clotet B., Karlsson A., Wohlfeiler M., Montana J.B., McHale M., Sullivan J., Ridgway C., Felstead S., Dunne M.W., van der Ryst E., Mayer H. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 2008, 359:1429-1441.
62. Gupta N., Fischer A.R., Frewer L.J. Socio-psychological determinants of public acceptance of technologies: a review. Public Underst. Sci. 2012, 21:782-795.
63. Gupta R.M., Musunuru K. Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J. Clin. Investig. 2014, 124:4154-4161.
64. Haapasalo K., Jarva H., Siljander T., Tewodros W., Vuopio-Varkila J., Jokiranta T.S. Complement factor H allotype 402H is associated with increased C3b opsonization and phagocytosis of Streptococcus pyogenes. Mol. Microbiol. 2008, 70:583-594.
65. Hale C.R., Majumdar S., Elmore J., Pfister N., Compton M., Olson S., Resch A.M., Glover C.V., Graveley B.R., Terns R.M., Terns M.P. Essential features and rational design of CRISPR RNAs that function with the Cas RAMP module complex to cleave RNAs. Mol. Cell 2012, 45:292-302.
66. Hayden E.C. Ethical dilemma for Ebola drug trials. Nature 2014, 515:177-178.
67. Heyer W.D., Ehmsen K.T., Liu J. Regulation of homologous recombination in eukaryotes. Annu. Rev. Genet. 2010, 44:113-139.
68. Hochstrasser M.L., Taylor D.W., Bhat P., Guegler C.K., Sternberg S.H., Nogales E., Doudna J.A. CasA mediates Cas3-catalyzed target degradation during CRISPR RNA-guided interference. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:6618-6623.
69. Holkers M., Maggio I., Henriques S.F., Janssen J.M., Cathomen T., Goncalves M.A. Adenoviral vector DNA for accurate genome editing with engineered nucleases. Nat. Methods 2014, 11:1051-1057.
70. Honkoop P., Scholte H.R., de Man R.A., Schalm S.W. Mitochondrial injury. Lessons from the fialuridine trial. Drug Saf. 1997, 17:1-7.
71. Hou Z., Zhang Y., Propson N.E., Howden S.E., Chu L.F., Sontheimer E.J., Thomson J.A. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:15644-15649.
72. Hsu P.D., Lander E.S., Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014, 157:1262-1278.
73. Hsu P.D., Scott D.A., Weinstein J.A., Ran F.A., Konermann S., Agarwala V., Li Y., Fine E.J., Wu X., Shalem O., Cradick T.J., Marraffini L.A., Bao G., Zhang F. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 2013, 31:827-832.
74. Huang X., Wang Y., Yan W., Smith C., Ye Z., Wang J., Gao Y., Mendelsohn L., Cheng L. Production of gene-corrected adult beta globin protein in human erythrocytes differentiated from patient ipscs after genome editing of the sickle point mutation. Stem Cells 2015, 33:1470-1479.
75. Hung S.C.C., Chrysostomou V., Li F., Lim J.K.H., Wang J.H., Powell J.E., Tu L.L., Daniszewski M., Lo C., Wong R.C., Crowston J.G., Pebay A., King A.E., Bui B.V., Liu G.S., Hewitt A.W. AAV-mediated CRISPR/Cas gene editing of retinal cells in vivo. bioRxiv 2016, 039156.
76. Ishino Y., Shinagawa H., Makino K., Amemura M., Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J. Bacteriol. 1987, 169:5429-5433.
77. Jacobson S.G., Cideciyan A.V., Ratnakaram R., Heon E., Schwartz S.B., Roman A.J., Peden M.C., Aleman T.S., Boye S.L., Sumaroka A., Conlon T.J., Calcedo R., Pang J.J., Erger K.E., Olivares M.B., Mullins C.L., Swider M., Kaushal S., Feuer W.J., Iannaccone A., Fishman G.A., Stone E.M., Byrne B.J., Hauswirth W.W. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch. Ophthalmol. 2012, 130:9-24.
78. Jansen R., Embden J.D., Gaastra W., Schouls L.M. Identification of genes that are associated with DNA repeats in prokaryotes. Mol. Microbiol. 2002, 43:1565-1575.
79. Jayathilaka K., Sheridan S.D., Bold T.D., Bochenska K., Logan H.L., Weichselbaum R.R., Bishop D.K., Connell P.P. A chemical compound that stimulates the human homologous recombination protein RAD51. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15848-15853.
80. Jiang W., Bikard D., Cox D., Zhang F., Marraffini L.A. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat. Biotechnol. 2013, 31:233-239.
81. Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012, 337:816-821.
82. Kabadi A.M., Ousterout D.G., Hilton I.B., Gersbach C.A. Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Res. 2014, 42:e147.
83. Kamao H., Mandai M., Okamoto S., Sakai N., Suga A., Sugita S., Kiryu J., Takahashi M. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Rep. 2014, 2:205-218.
84. Kanemura H., Go M.J., Shikamura M., Nishishita N., Sakai N., Kamao H., Mandai M., Morinaga C., Takahashi M., Kawamata S. Tumorigenicity studies of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of age-related macular degeneration. PLoS One 2014, 9:e85336.
85. Karlsdotter K., Martin Martin J.J., Lopez del Amo Gonzalez M.P. Multilevel analysis of income, income inequalities and health in Spain. Soc. Sci. Med. 2012, 74:1099-1106.
86. Karvelis T., Gasiunas G., Miksys A., Barrangou R., Horvath P., Siksnys V. crRNA and tracrRNA guide Cas9-mediated DNA interference in Streptococcus thermophilus. RNA Biol. 2013, 10:841-851.
87. Kim D., Bae S., Park J., Kim E., Kim S., Yu H.R., Hwang J., Kim J.I., Kim J.S. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat. Methods 2015, 12:237-243. 231 p following 243.
88. Kim S., Kim D., Cho S.W., Kim J., Kim J.S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014, 24:1012-1019.
89. Kim Y.G., Cha J., Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:1156-1160.
90. Kiskinis E., Sandoe J., Williams L.A., Boulting G.L., Moccia R., Wainger B.J., Han S., Peng T., Thams S., Mikkilineni S., Mellin C., Merkle F.T., Davis-Dusenbery B.N., Ziller M., Oakley D., Ichida J., Di Costanzo S., Atwater N., Maeder M.L., Goodwin M.J., Nemesh J., Handsaker R.E., Paull D., Noggle S., McCarroll S.A., Joung J.K., Woolf C.J., Brown R.H., Eggan K. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell 2014, 14:781-795.
91. Kleinstiver B.P., Pattanayak V., Prew M.S., Tsai S.Q., Nguyen N.T., Zheng Z., Joung J.K. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 2016, 529:490-495.
92. Kleinstiver B.P., Prew M.S., Tsai S.Q., Nguyen N.T., Topkar V.V., Zheng Z., Joung J.K. Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat. Biotechnol. 2015, 33:1293-1298.
93. Kleinstiver B.P., Prew M.S., Tsai S.Q., Topkar V.V., Nguyen N.T., Zheng Z., Gonzales A.P., Li Z., Peterson R.T., Yeh J.R., Aryee M.J., Joung J.K. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 2015, 523:481-485.
94. Klenk H.P., Clayton R.A., Tomb J.F., White O., Nelson K.E., Ketchum K.A., Dodson R.J., Gwinn M., Hickey E.K., Peterson J.D., Richardson D.L., Kerlavage A.R., Graham D.E., Kyrpides N.C., Fleischmann R.D., Quackenbush J., Lee N.H., Sutton G.G., Gill S., Kirkness E.F., Dougherty B.A., McKenney K., Adams M.D., Loftus B., Peterson S., Reich C.I., McNeil L.K., Badger J.H., Glodek A., Zhou L., Overbeek R., Gocayne J.D., Weidman J.F., McDonald L., Utterback T., Cotton M.D., Spriggs T., Artiach P., Kaine B.P., Sykes S.M., Sadow P.W., D'Andrea K.P., Bowman C., Fujii C., Garland S.A., Mason T.M., Olsen G.J., Fraser C.M., Smith H.O., Woese C.R., Venter J.C. The complete genome sequence of the hyperthermophilic, sulphate-reducing archaeon Archaeoglobus fulgidus. Nature 1997, 390:364-370.
95. Komor A.C., Kim Y.B., Packer M.S., Zuris J.A., Liu D.R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 2016, 533:420-424.
96. Konermann S., Brigham M.D., Trevino A.E., Joung J., Abudayyeh O.O., Barcena C., Hsu P.D., Habib N., Gootenberg J.S., Nishimasu H., Nureki O., Zhang F. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 2015, 517:583-588.
97. Kunin V., Sorek R., Hugenholtz P. Evolutionary conservation of sequence and secondary structures in CRISPR repeats. Genome Biol. 2007, 8:R61.
98. Kuscu C., Arslan S., Singh R., Thorpe J., Adli M. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat. Biotechnol. 2014, 32:677-683.
99. Lanphier E., Urnov F., Haecker S.E., Werner M., Smolenski J. Don't edit the human germ line. Nature 2015, 519:410-411.
100. Li T., Adamian M., Roof D.J., Berson E.L., Dryja T.P., Roessler B.J., Davidson B.L. In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector. Investig. Ophthalmol. Vis. Sci. 1994, 35:2543-2549.
101. Liang P., Xu Y., Zhang X., Ding C., Huang R., Zhang Z., Lv J., Xie X., Chen Y., Li Y., Sun Y., Bai Y., Songyang Z., Ma W., Zhou C., Huang J. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 2015, 6:363-372.
102. Liew G., Michaelides M., Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open 2014, 4:e004015.
103. Lin S., Staahl B.T., Alla R.K., Doudna J.A. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife 2014, 3:e04766.
104. Lin Y., Cradick T.J., Brown M.T., Deshmukh H., Ranjan P., Sarode N., Wile B.M., Vertino P.M., Stewart F.J., Bao G. CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res. 2014, 42:7473-7485.
105. Liu M.M., Tuo J., Chan C.C. Republished review: gene therapy for ocular diseases. Postgrad. Med. J. 2011, 87:487-495.
106. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E., Stuhlmann H., Koup R.A., Landau N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
107. Ma E., Harrington L.B., O'Connell M.R., Zhou K., Doudna J.A. Single-stranded DNA cleavage by divergent CRISPR-Cas9 enzymes. Mol. Cell 2015, 60:398-407.
108. MacLaren R.E., Groppe M., Barnard A.R., Cottriall C.L., Tolmachova T., Seymour L., Clark K.R., During M.J., Cremers F.P., Black G.C., Lotery A.J., Downes S.M., Webster A.R., Seabra M.C. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 2014, 383:1129-1137.
109. Maggio I., Holkers M., Liu J., Janssen J.M., Chen X., Goncalves M.A. Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells. Sci. Rep. 2014, 4:5105.
110. Makarova K.S., Aravind L., Wolf Y.I., Koonin E.V. Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems. Biol. Direct 2011, 6:38.
111. Makarova K.S., Haft D.H., Barrangou R., Brouns S.J., Charpentier E., Horvath P., Moineau S., Mojica F.J., Wolf Y.I., Yakunin A.F., van der Oost J., Koonin E.V. Evolution and classification of the CRISPR-Cas systems. Nat. Rev. Microbiol. 2011, 9:467-477.
112. Makarova K.S., Wolf Y.I., Alkhnbashi O.S., Costa F., Shah S.A., Saunders S.J., Barrangou R., Brouns S.J., Charpentier E., Haft D.H., Horvath P., Moineau S., Mojica F.J., Terns R.M., Terns M.P., White M.F., Yakunin A.F., Garrett R.A., van der Oost J., Backofen R., Koonin E.V. An updated evolutionary classification of CRISPR-Cas systems. Nat. Rev. Microbiol. 2015, 13:722-736.
113. Mali P., Aach J., Stranges P.B., Esvelt K.M., Moosburner M., Kosuri S., Yang L., Church G.M. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 2013, 31:833-838.
114. Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., Norville J.E., Church G.M. RNA-guided human genome engineering via Cas9. Science 2013, 339:823-826.
115. Mandal P.K., Ferreira L.M., Collins R., Meissner T.B., Boutwell C.L., Friesen M., Vrbanac V., Garrison B.S., Stortchevoi A., Bryder D., Musunuru K., Brand H., Tager A.M., Allen T.M., Talkowski M.E., Rossi D.J., Cowan C.A. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 2014, 15:643-652.
116. Mandell J.G., Barbas C.F. Zinc Finger Tools: custom DNA-binding domains for transcription factors and nucleases. Nucleic Acids Res. 2006, 34:W516-W523.
117. Marraffini L.A., Sontheimer E.J. Self versus non-self discrimination during CRISPR RNA-directed immunity. Nature 2010, 463:568-571.
118. Maruyama T., Dougan S.K., Truttmann M.C., Bilate A.M., Ingram J.R., Ploegh H.L. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat. Biotechnol. 2015, 33:538-542.
119. Mashal R.D., Koontz J., Sklar J. Detection of mutations by cleavage of DNA heteroduplexes with bacteriophage resolvases. Nat. Genet. 1995, 9:177-183.
120. McCaughey T., Sanfilippo P.G., Gooden G.E.C., Budden D.M., Fan L., Fenwick E., Rees G., MacGregor C., Si L., Chen C., Liang H.H., Baldwin T., Pébay A., Hewitt A.W. A global social media survey of attitudes to human genome editing. Cell Stem Cell 2016, 18:569-572.
121. Miller J.C., Tan S., Qiao G., Barlow K.A., Wang J., Xia D.F., Meng X., Paschon D.E., Leung E., Hinkley S.J., Dulay G.P., Hua K.L., Ankoudinova I., Cost G.J., Urnov F.D., Zhang H.S., Holmes M.C., Zhang L., Gregory P.D., Rebar E.J. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 2011, 29:143-148.
122. Mitalipov S., Wolf D.P. Clinical and ethical implications of mitochondrial gene transfer. Trends Endocrinol. Metab. 2014, 25:5-7.
123. Mohler S.R. Human factors of powered flight: the Wright brothers' contributions. Aviat. Space Environ. Med. 2004, 75:184-188.
124. Mojica F.J., Diez-Villasenor C., Garcia-Martinez J., Almendros C. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 2009, 155:733-740.
125. Mojica F.J., Diez-Villasenor C., Soria E., Juez G. Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. Mol. Microbiol. 2000, 36:244-246.
126. Mojica F.J., Ferrer C., Juez G., Rodriguez-Valera F. Long stretches of short tandem repeats are present in the largest replicons of the Archaea Haloferax mediterranei and Haloferax volcanii and could be involved in replicon partitioning. Mol. Microbiol. 1995, 17:85-93.
127. Morrison C. $1-million price tag set for Glybera gene therapy. Nat. Biotechnol. 2015, 33:217-218.
128. Nelson K.E., Clayton R.A., Gill S.R., Gwinn M.L., Dodson R.J., Haft D.H., Hickey E.K., Peterson J.D., Nelson W.C., Ketchum K.A., McDonald L., Utterback T.R., Malek J.A., Linher K.D., Garrett M.M., Stewart A.M., Cotton M.D., Pratt M.S., Phillips C.A., Richardson D., Heidelberg J., Sutton G.G., Fleischmann R.D., Eisen J.A., White O., Salzberg S.L., Smith H.O., Venter J.C., Fraser C.M. Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature 1999, 399:323-329.
129. Nissim L., Perli S.D., Fridkin A., Perez-Pinera P., Lu T.K. Multiplexed and programmable regulation of gene networks with an integrated RNA and CRISPR/Cas toolkit in human cells. Mol. Cell 2014, 54:698-710.
130. Ousterout D.G., Kabadi A.M., Thakore P.I., Majoros W.H., Reddy T.E., Gersbach C.A. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat. Commun. 2015, 6:6244.
131. Pang J.J., Chang B., Kumar A., Nusinowitz S., Noorwez S.M., Li J., Rani A., Foster T.C., Chiodo V.A., Doyle T., Li H., Malhotra R., Teusner J.T., McDowell J.H., Min S.H., Li Q., Kaushal S., Hauswirth W.W. Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol. Ther. 2006, 13:565-572.
132. Parnas O., Jovanovic M., Eisenhaure T.M., Herbst R.H., Dixit A., Ye C.J., Przybylski D., Platt R.J., Tirosh I., Sanjana N.E., Shalem O., Satija R., Raychowdhury R., Mertins P., Carr S.A., Zhang F., Hacohen N., Regev A. A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks. Cell 2015, 162:675-686.
133. Pattanayak V., Lin S., Guilinger J.P., Ma E., Doudna J.A., Liu D.R. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat. Biotechnol. 2013, 31:839-843.
134. Pennisi E. The CRISPR craze. Science 2013, 341:833-836.
135. Pickett K.E., Wilkinson R.G. Income inequality and health: a causal review. Soc. Sci. Med. 2015, 128:316-326.
136. Pollack R. Eugenics lurk in the shadow of CRISPR. Science 2015, 348:871.
137. Powledge T.M. Research on human embryonic stem cells. NIH issues new guidelines a week after British recommendations. EMBO Rep. 2000, 1:297-298.
138. Qiu P., Shandilya H., D'Alessio J.M., O'Connor K., Durocher J., Gerard G.F. Mutation detection using surveyor nuclease. Biotechniques 2004, 36:702-707.
139. Rajan K., Kennedy J., King L. Is wealthier always healthier in poor countries? the health implications of income, inequality, poverty, and literacy in India. Soc. Sci. Med. 2013, 88:98-107.
140. Ran F.A., Cong L., Yan W.X., Scott D.A., Gootenberg J.S., Kriz A.J., Zetsche B., Shalem O., Wu X., Makarova K.S., Koonin E.V., Sharp P.A., Zhang F. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015, 520:186-191.
141. Ran F.A., Hsu P.D., Lin C.Y., Gootenberg J.S., Konermann S., Trevino A.E., Scott D.A., Inoue A., Matoba S., Zhang Y., Zhang F. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013, 154:1380-1389.
142. Robillard J.M., Roskams-Edris D., Kuzeljevic B., Illes J. Prevailing public perceptions of the ethics of gene therapy. Hum. Gene Ther. 2014, 25:740-746.
143. Roosing S., Thiadens A.A., Hoyng C.B., Klaver C.C., den Hollander A.I., Cremers F.P. Causes and consequences of inherited cone disorders. Prog. Retin Eye Res. 2014, 42:1-26.
144. Sakuma T., Nishikawa A., Kume S., Chayama K., Yamamoto T. Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system. Sci. Rep. 2014, 4:5400.
145. Sambrook J., Russel D.W. Molecular Cloning: A Laboratory Manual 2001, Cold Spring Harbor, New York. third ed.
146. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collman R.G., Doms R.W., Vassart G., Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
147. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 2004, 73:39-85.
148. Sandel M.J. The case against perfection: what's wrong with designer children, bionic athletes, and genetic engineering. Atl. Mon. 2004, 292:50-54. 56-60, 62.
149. Sapranauskas R., Gasiunas G., Fremaux C., Barrangou R., Horvath P., Siksnys V. The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res. 2011, 39:9275-9282.
150. Savulescu J. Education and debate: deaf lesbians, "designer disability," and the future of medicine. BMJ 2002, 325:771-773.
151. Scully J.L. What is a disease?. EMBO Rep. 2004, 5:650-653.
152. Semenova E., Jore M.M., Datsenko K.A., Semenova A., Westra E.R., Wanner B., van der Oost J., Brouns S.J., Severinov K. Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:10098-10103.
153. Senis E., Fatouros C., Grosse S., Wiedtke E., Niopek D., Mueller A.K., Borner K., Grimm D. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. Biotechnol. J. 2014, 9:1402-1412.
154. Shalem O., Sanjana N.E., Hartenian E., Shi X., Scott D.A., Mikkelsen T.S., Heckl D., Ebert B.L., Root D.E., Doench J.G., Zhang F. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014, 343:84-87.
155. Shmakov S., Abudayyeh O.O., Makarova K.S., Wolf Y.I., Gootenberg J.S., Semenova E., Minakhin L., Joung J., Konermann S., Severinov K., Zhang F., Koonin E.V. Discovery and functional characterization of diverse class 2 CRISPR-Cas systems. Mol. Cell 2015, 60:385-397.
156. Singh P., Schimenti J.C., Bolcun-Filas E. A mouse geneticist's practical guide to CRISPR applications. Genetics 2015, 199:1-15.
157. Sinkunas T., Gasiunas G., Fremaux C., Barrangou R., Horvath P., Siksnys V. Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas immune system. EMBO J. 2011, 30:1335-1342.
158. Slaymaker I.M., Gao L., Zetsche B., Scott D.A., Yan W.X., Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science 2016, 351:84-88.
159. Smith C., Abalde-Atristain L., He C., Brodsky B.R., Braunstein E.M., Chaudhari P., Jang Y.Y., Cheng L., Ye Z. Efficient and allele-specific genome editing of disease loci in human iPSCs. Mol. Ther. 2015, 23:570-577.
160. Smith C., Gore A., Yan W., Abalde-Atristain L., Li Z., He C., Wang Y., Brodsky R.A., Zhang K., Cheng L., Ye Z. Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell 2014, 15:12-13.
161. Song J., Yang D., Xu J., Zhu T., Chen Y.E., Zhang J. RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency. Nat. Commun. 2016, 7:10548.
162. Suzuki K., Yu C., Qu J., Li M., Yao X., Yuan T., Goebl A., Tang S., Ren R., Aizawa E., Zhang F., Xu X., Soligalla R.D., Chen F., Kim J., Kim N.Y., Liao H.K., Benner C., Esteban C.R., Jin Y., Liu G.H., Li Y., Izpisua Belmonte J.C. Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. Cell Stem Cell 2014, 15:31-36.
163. Swiech L., Heidenreich M., Banerjee A., Habib N., Li Y., Trombetta J., Sur M., Zhang F. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 2015, 33:102-106.
164. Tachibana M., Amato P., Sparman M., Woodward J., Sanchis D.M., Ma H., Gutierrez N.M., Tippner-Hedges R., Kang E., Lee H.S., Ramsey C., Masterson K., Battaglia D., Lee D., Wu D., Jensen J., Patton P., Gokhale S., Stouffer R., Mitalipov S. Towards germline gene therapy of inherited mitochondrial diseases. Nature 2013, 493:627-631.
165. Tachibana M., Sparman M., Sritanaudomchai H., Ma H., Clepper L., Woodward J., Li Y., Ramsey C., Kolotushkina O., Mitalipov S. Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature 2009, 461:367-372.
166. Takata M., Sasaki M.S., Sonoda E., Morrison C., Hashimoto M., Utsumi H., Yamaguchi-Iwai Y., Shinohara A., Takeda S. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J. 1998, 17:5497-5508.
167. Tebas P., Stein D., Tang W.W., Frank I., Wang S.Q., Lee G., Spratt S.K., Surosky R.T., Giedlin M.A., Nichol G., Holmes M.C., Gregory P.D., Ando D.G., Kalos M., Collman R.G., Binder-Scholl G., Plesa G., Hwang W.T., Levine B.L., June C.H. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 2014, 370:901-910.
168. Testa F., Maguire A.M., Rossi S., Pierce E.A., Melillo P., Marshall K., Banfi S., Surace E.M., Sun J., Acerra C., Wright J.F., Wellman J., High K.A., Auricchio A., Bennett J., Simonelli F. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 2013, 120:1283-1291.
169. Torjesen I. UK moves a step closer to being first country in world to allow "three parent babies. BMJ 2013, 346:f1899.
170. Trapani I., Banfi S., Simonelli F., Surace E.M., Auricchio A. Gene therapy of inherited retinal degenerations: prospects and challenges. Hum. Gene Ther. 2015, 26:193-200.
171. Travis J. GENETIC ENGINEERING. Germline editing dominates DNA summit. Science 2015, 350:1299-1300.
172. Tsai S.Q., Wyvekens N., Khayter C., Foden J.A., Thapar V., Reyon D., Goodwin M.J., Aryee M.J., Joung J.K. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat. Biotechnol. 2014, 32:569-576.
173. Tsai S.Q., Zheng Z., Nguyen N.T., Liebers M., Topkar V.V., Thapar V., Wyvekens N., Khayter C., Iafrate A.J., Le L.P., Aryee M.J., Joung J.K. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 2015, 33:187-197.
174. Tucker B.A., Mullins R.F., Stone E.M. Stem cells for investigation and treatment of inherited retinal disease. Hum. Mol. Genet. 2014, 23:R9-R16.
175. Vanamee E.S., Santagata S., Aggarwal A.K. FokI requires two specific DNA sites for cleavage. J. Mol. Biol. 2001, 309:69-78.
176. Veres A., Gosis B.S., Ding Q., Collins R., Ragavendran A., Brand H., Erdin S., Cowan C.A., Talkowski M.E., Musunuru K. Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell 2014, 15:27-30.
177. Wah D.A., Hirsch J.A., Dorner L.F., Schildkraut I., Aggarwal A.K. Structure of the multimodular endonuclease FokI bound to DNA. Nature 1997, 388:97-100.
178. Wakefield J.C. The concept of mental disorder. On the boundary between biological facts and social values. Am. Psychol. 1992, 47:373-388.
179. Wang T., Wei J.J., Sabatini D.M., Lander E.S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 2014, 343:80-84.
180. Wang X., Wang Y., Wu X., Wang J., Wang Y., Qiu Z., Chang T., Huang H., Lin R.J., Yee J.K. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat. Biotechnol. 2015, 33:175-178.
181. Westra E.R., van Erp P.B., Kunne T., Wong S.P., Staals R.H., Seegers C.L., Bollen S., Jore M.M., Semenova E., Severinov K., de Vos W.M., Dame R.T., de Vries R., Brouns S.J., van der Oost J. CRISPR immunity relies on the consecutive binding and degradation of negatively supercoiled invader DNA by Cascade and Cas3. Mol. Cell 2012, 46:595-605.
182. Whetstine L.M. Ethical challenges in assisted reproduction: the place of preimplantation genetic diagnosis in a just society. J. Child. Neurol. 2015, 30:547-550.
183. Wiley L.A., Burnight E.R., Songstad A.E., Drack A.V., Mullins R.F., Stone E.M., Tucker B.A. Patient-specific induced pluripotent stem cells (iPSCs) for the study and treatment of retinal degenerative diseases. Prog. Retin Eye Res. 2015, 44:15-35.
184. Wilmut I., Leslie S., Martin N.G., Peschanski M., Rao M., Trounson A., Turner D., Turner M.L., Yamanaka S., Taylor C.J. Development of a global network of induced pluripotent stem cell haplobanks. Regen. Med. 2015, 10:235-238.
185. Wu X., Scott D.A., Kriz A.J., Chiu A.C., Hsu P.D., Dadon D.B., Cheng A.W., Trevino A.E., Konermann S., Chen S., Jaenisch R., Zhang F., Sharp P.A. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat. Biotechnol. 2014, 32:670-676.
186. Wyvekens N., Topkar V.V., Khayter C., Joung J.K., Tsai S.Q. Dimeric CRISPR RNA-guided FokI-dCas9 nucleases directed by truncated gRNAs for highly specific genome editing. Hum. Gene Ther. 2015, 26:425-431.
187. Xiao A., Wu Y., Yang Z., Hu Y., Wang W., Zhang Y., Kong L., Gao G., Zhu Z., Lin S., Zhang B. EENdb: a database and knowledge base of ZFNs and TALENs for endonuclease engineering. Nucleic Acids Res. 2013, 41:D415-D422.
188. Xie K., Minkenberg B., Yang Y. Boosting CRISPR/Cas9 multiplex editing capability with the endogenous tRNA-processing system. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:3570-3575.
189. Xu T., Li Y., Van Nostrand J.D., He Z., Zhou J. Cas9-based tools for targeted genome editing and transcriptional control. Appl. Environ. Microbiol. 2014, 80:1544-1552.
190. Yang L., Grishin D., Wang G., Aach J., Zhang C.Z., Chari R., Homsy J., Cai X., Zhao Y., Fan J.B., Seidman C., Seidman J., Pu W., Church G. Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells. Nat. Commun. 2014, 5:5507.
191. Yang L., Guell M., Niu D., George H., Lesha E., Grishin D., Aach J., Shrock E., Xu W., Poci J., Cortazio R., Wilkinson R.A., Fishman J.A., Church G. Genome-wide inactivation of porcine endogenous retroviruses (PERVs). Science 2015, 350:1101-1104.
192. Yarborough M., Sharp R.R. Public trust and research a decade later: what have we learned since Jesse Gelsinger's death?. Mol. Genet. Metab. 2009, 97:4-5.
193. Yen S.T., Zhang M., Deng J.M., Usman S.J., Smith C.N., Parker-Thornburg J., Swinton P.G., Martin J.F., Behringer R.R. Somatic mosaicism and allele complexity induced by CRISPR/Cas9 RNA injections in mouse zygotes. Dev. Biol. 2014, 393:3-9.
194. Yin H., Xue W., Chen S., Bogorad R.L., Benedetti E., Grompe M., Koteliansky V., Sharp P.A., Jacks T., Anderson D.G. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 2014, 32:551-553.
195. Yu C., Liu Y., Ma T., Liu K., Xu S., Zhang Y., Liu H., La Russa M., Xie M., Ding S., Qi L.S. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 2015, 16:142-147.
196. Zeitz C., Robson A.G., Audo I. Congenital stationary night blindness: an analysis and update of genotype-phenotype correlations and pathogenic mechanisms. Prog. Retin Eye Res. 2015, 45:58-110.
197. Zetsche B., Gootenberg J.S., Abudayyeh O.O., Slaymaker I.M., Makarova K.S., Essletzbichler P., Volz S.E., Joung J., van der Oost J., Regev A., Koonin E.V., Zhang F. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 2015, 163:759-771.
198. Zetsche B., Volz S.E., Zhang F. A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat. Biotechnol. 2015, 33:139-142.
199. Zhou R., Caspi R.R. Ocular immune privilege. Biol. Rep. 2010, 2. F1000.
200. Zuris J.A., Thompson D.B., Shu Y., Guilinger J.P., Bessen J.L., Hu J.H., Maeder M.L., Joung J.K., Chen Z.Y., Liu D.R. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 2015, 33:73-80.